112 results about "Psychogenic disease" patented technology

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

This disclosure relates to a method of treating a neurological disorder, comprising administering a bupropion, or a combination of a bupropion and a dextromethorphan, to a human being in need thereof, monitoring the human being for Brugada pattern / syndrome, drug reaction with eosinophilia and systemic symptoms, or acute generalized exanthematous pustulosis, and reducing or discontinuing use of the bupropion, or the combination of the bupropion and the dextromethorphan, if the human being develops Brugada pattern / syndrome, subcutaneous tissue disorder, drug reaction with eosinophilia and systemic symptoms (DRESS), or acute generalized exanthematous pustulosis.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in human patients for treating neurological and psychiatric conditions, such as agitation associated Alzheimer's disease and / or reducing relapse of agitation in Alzheimer's disease.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Accordingly, the present invention relates to compounds of formula (Id)whereinR1 is H and R2 is selected from one of the substituents (i) and (ii) below; orR1 is selected from one of the substituents (i) and (ii) below and R2 is H; orR1 and R2 are both represented by substituent (i) below; orR1 and R2 are both represented by substituent (ii) below; orR1 is substituent (i) and R2 is substituent (ii); orR1 is substituent (ii) and R2 is substituent (i);wherein * indicates the attachment point; andwherein the carbon atom at the attachment point on substituent (i) is in the S-configuration;or a pharmaceutically acceptable salt thereof.

This invention belongs to the field of medicinal chemistry, specifically relating to benzofuran compounds or their pharmaceutically acceptable salts, their preparation methods, and applications. The benzofuran compounds of this invention can significantly inhibit the activity of phosphodiesterase 4 and can be used to prepare drugs for treating inflammatory diseases, autoimmune diseases, or neuropsychiatric disorders, especially for stroke and ischemic dementia-related diseases.

To provide arylcyclohexylamine compounds and their use in the treatment of psychiatric disorders.SOLUTION: There are provided arylcyclohexylamine compounds and compositions of a single enantiomer or enantiomerically enriched mixtures of arylcyclohexylamine having significantly higher oral bioavailability, higher antidepressant potency, and / or greater therapeutic index between antidepressant effects and side effects, compared to ketamine.SELECTED DRAWING: None

This specification discloses a method for administering dexmedetomidine or a pharmaceutically acceptable salt thereof to human subjects. The disclosed method is particularly suitable for the treatment of agitation associated with neurodegenerative diseases and / or neuropsychiatric disorders or disorders (e.g., Alzheimer's disease).

The present disclosure relates to methods of treating agitation, comprising administering (S)-(3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol to a mammal in need thereof. Agitation is a common behavioral symptom in neurodegenerative and neuropsychiatric disorders. Disclosed herein are methods of treating agitation. These methods comprise administering (S)-(3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol to a mammal in need thereof.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2-oxopyrrolidin-1-yl)propanamide derivatives with R-configuration at the stereogenic center are disclosed, showing broad-spectrum protective activity in animal models of epileptic seizures, pain, depression and anxiety that are simultaneously devoid of undesirable sedative effects. Additionally, the disclosed derivatives have neuroprotective effects in the in vitro and in vivo studies.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Compounds having a 3,4,6-substituted benzocyclobuten-1-yl-methylamine structure, pharmaceutical compositions and methods employing use thereof for treating acute or chronic bipolar disorders, neuropsychiatric disorders, neurodegenerative conditions and other health conditions associated with neuronal excitability or dysregulated synaptic neurotransmission. The disclosed compounds selectively and rapidly reduce the frequency of action potentials in cortical pyramidal neurons by modulating presynaptic glutamate release while preserving GABAergic neurotransmission and single action potential properties. Selective modulation of excitatory neurotransmission achieves rapid therapeutic effects within minutes to hours after ingestion without disrupting inhibitory transmission, presenting a therapeutic approach for neurological conditions characterized by neuronal hyperexcitability and other pathological excitatory-inhibitory neurotransmission imbalance.

The present invention is directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives, advantageously for use in the prevention or treatment of neurological, psychiatric and sleep disorders and diseases in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds for use in the prevention and / or treatment of neurological disorders and diseases. The present invention is also directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives and the use of these compounds as medicaments.

Provided are crystalline forms of 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine, pharmaceutical compositions comprising the crystalline form, and their use in treating conditions associated with TARP γ8-dependent AMPA activity, such as epilepsy, epileptic disorders, seizures, seizure disorders, pain, psychiatric diseases, or neurodegenerative diseases.

The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

Disclosed herein is a method of treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and are CYP2D6 poor metabolizers.

To provide dosage forms and compositions useful for preventing and / or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)).SOLUTION: Provided is an oral dosage form comprising: a compound of the following formula or a pharmaceutically acceptable salt thereof; and a modified-release polymer.SELECTED DRAWING: None

The invention discloses an application of aureomycin in preparation of a medicine for preventing and treating depression or anxiety behaviors. Experimental results indicate that AUN (aureusidin) can effectively increase the exploration frequency and the retention time of a model mouse on an open arm of an elevated cross labyrinth, improve the activity of the model mouse in a central area of an open field and remarkably improve depression or anxiety behaviors of the model mouse. The invention proves that the AUN has a potential effect of preventing and treating depression or anxiety behaviors, provides an experimental basis and theoretical support for developing novel medicines for treating neuropsychiatric diseases by using natural products, and has a wide application prospect.

Provided herein are methods of treating a seizure disorder in a subject in need thereof comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Also provided are methods of treating a pain, neurological, or psychiatric disorder, and methods of administering seletracetam to a subject comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Various pharmaceutical formulations comprising seletracetam, e.g., an orally disintegrating tablet and a mucoadhesive film, and a nasal spray device or oromucosal spray device comprising seletracetam are also provided.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

Provided herein, inter alia, are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Compounds having a 3,4,6-substituted benzocyclobuten-1-yl-methylamine structure, pharmaceutical compositions and methods employing use thereof for treating acute or chronic bipolar disorders, neuropsychiatric disorders, neurodegenerative conditions and other health conditions associated with neuronal excitability or dysregulated synaptic neurotransmission. The disclosed compounds selectively and rapidly reduce the frequency of action potentials in cortical pyramidal neurons by modulating presynaptic glutamate release while preserving GABAergic neurotransmission and single action potential properties. Selective modulation of excitatory neurotransmission achieves rapid therapeutic effects within minutes to hours after ingestion without disrupting inhibitory transmission, presenting a therapeutic approach for neurological conditions characterized by neuronal hyperexcitability and other pathological excitatory-inhibitory neurotransmission imbalance.